Evidence map›Paper›PMID 29963059›Full record

ArticleFrontiers in immunology2018

Predicting HLA CD4 Immunogenicity in Human Populations.

Sandeep Kumar Dhanda, Edita Karosiene, Lindy Edwards, Alba Grifoni, Sinu Paul, Massimo Andreatta, Daniela Weiskopf, John Sidney, Morten Nielsen, Bjoern Peters and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 141 citations in OpenAlex.

  1. Article
  2. Article
  3. Predicting Neoantigen Immunogenicity frombioRxiv : the preprint server for biology · 2026
    Article
  4. Technical review of artificial intelligence in TCR-T therapy.Journal of the National Cancer Center · 2026
    Review
  5. Article
  6. Article
  7. Decoding the human CD4Cell reports. Medicine · 2026
    Article
  8. Comprehensive mapping of human CD4Cell reports. Medicine · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Sandeep Kumar DhandaDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Edita KarosieneDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Lindy EdwardsDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Alba GrifoniDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Sinu PaulDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Massimo AndreattaInstituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, Buenos Aires, Argentina.
Daniela WeiskopfDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Morten NielsenInstituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, Buenos Aires, Argentina.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
La Jolla Institute for Immunology · USNational University of General San Martín · AR

Funding

Inner City Asthma consortium 3 (ICAC3)UM1AI114271 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI GERN, JAMES E., JACKSON, DANIEL J · 2014 to 2021
$79.4M
Single-cell atlas of lung tissue-resident memory T cells reactive to upper and lower respiratory tract pathogensU19AI118626 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Bjoern Peters · 2015 to 2026
$36.7M
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Aravinda M. DeSilva · 2015 to 2026
$34.1M
Role of antigen-specific T cell responses in the control of TBU19AI111211 · NIAID · EMORY UNIVERSITY · PI BLUMBERG, HENRY M, ERNST, JOEL D. · 2014 to 2020
$20.1M
Understanding mechanisms in specific immunotherapy (SIT)U19AI100275 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SETTE, ALESSANDRO · 2012 to 2017
$8.1M
NIAID NIH HHS HHSN272200900042CNIAID NIH HHS HHSN272201200010CNIAID NIH HHS P01 AI106695NIAID NIH HHS U19 AI100275NIAID NIH HHS U19 AI111211NIAID NIH HHS U19 AI118626NIAID NIH HHS UM1 AI114271
6 · The paper itself

Abstract

backgroundPrediction of T cell immunogenicity is a topic of considerable interest, both in terms of basic understanding of the mechanisms of T cells responses and in terms of practical applications. HLA binding affinity is often used to predict T cell epitopes, since HLA binding affinity is a key requisite for human T cell immunogenicity. However, immunogenicity at the population it is complicated by the high level of variability of HLA molecules, potential other factors beyond HLA as well as the frequent lack of HLA typing data. To overcome those issues, we explored an alternative approach to identify the common characteristics able to distinguish immunogenic peptides from non-recognized peptides.

methodsSets of dominant epitopes derived from peer-reviewed published papers were used in conjunction with negative peptides from the same experiments/donors to train neural networks and generate an "immunogenicity score." We also compared the performance of the immunogenicity score with previously described method for immunogenicity prediction based on HLA class II binding at the population level.

resultsThe immunogenicity score was validated on a series of independent datasets derived from the published literature, representing 57 independent studies where immunogenicity in human populations was assessed by testing overlapping peptides spanning different antigens. Overall, these testing datasets corresponded to over 2,000 peptides and tested in over 1,600 different human donors. The 7-allele method prediction and the immunogenicity score were associated with similar performance [average area under the ROC curve (AUC) values of 0.703 and 0.702, respectively] while the combined methods reached an average AUC of 0.725. This increase in average AUC value is significant compared with the immunogenicity score (

conclusionThe new immunogenicity score predicts CD4 T cell immunogenicity at the population level starting from protein sequences and with no need for HLA typing. Its efficacy has been validated in the context of different antigen sources, ethnicities, and disparate techniques for epitope identification.

Indexed as

bioinformaticsepitopesHLAimmunodominanceimmunogenicitypredictionsTCR repertoire

Identifiers

PMID29963059
PMCPMC6010533
OpenAlexW2806925824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.